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Data from 1,700 patients living in southern Benin were
collected at the Centre Sanitaire et Nutritionnel Gbemoten,
Zagnanado, Benin, from 1997 through 2001. In the Zou
region in 1999, Buruli ulcer (BU) had a higher detection rate
(21.5/100,000) than leprosy (13.4/100,000) and tuberculo-
sis (20.0/100,000). More than 13% of the patients had
osteomyelitis. Delay in seeking treatment declined from 4
months in 1989 to 1 month in 2001, and median hospital-
ization time decreased from 9 months in 1989 to 1 month
in 2001. This reduction is attributed, in part, to implement-
ing an international cooperation program, creating a nation-
al BU program, and making advances in patient care.
B
uruli ulcer (BU), caused by Mycobacterium ulcerans,
is the third most common mycobacterial disease in
humans after tuberculosis and leprosy (1). Endemic foci
exist in tropical Africa, the Americas, Australia, and Asia
(1–3). In 1997, the World Health Organization recognized
BU as an emerging public health problem. Prevalences
have increased during the last few years, especially in West
Africa (4–7). 
M. ulcerans is an environmental mycobacterium asso-
ciated with wetlands, especially slow-flowing or stagnant
water (8–10). Infection is often related to specific trauma
(11). Aquatic insects may play a role in transmitting BU to
humans (12,13). Naturally acquired M. ulcerans infection
in wild animals (14) suggests that the etiologic agent is an
environmental organism. Most authorities divide BU
lesions in the skin into three clinical categories: nonulcer-
ative forms (papules, nodules, indurated plaques, or
edema), ulcerative forms, and the healing or scarring form
(1,6). Bone lesions also exist (15).
Even though large numbers of patients have been
reported, the epidemiology of BU remains obscure, even in
disease-endemic countries. In 1997, a first report was pub-
lished on 867 BU patients from the Republic of Benin
(West Africa) for 1989–1996 (4). Our study covers the
ensuing 5 years (1997 to 2001), during which a collabora-
tive project was initiated to improve detection and control
of BU. This study describes BU in Benin and presents
demographic trends and epidemiologic data from the four
southern regions of Benin (Zou, Oueme, Mono, and
Atlantique), as seen in a rural hospital in the Zou Region.
Patients and Methods
Our observations are based on 1,700 consecutive
patients diagnosed with BU and admitted from 1997 to
2001 to the Centre Sanitaire et Nutritionnel Gbemoten
(CSNG), at Zagnanado in the Zou Region. Age, sex, ori-
gin, date of disease onset as reported by the patient, date of
diagnosis, duration of hospitalization, clinical characteris-
tics, and evolution of the disease were recorded. Clinical
criteria for suspecting BU included: presence of a chroni-
cally developing lesion (several weeks or months), i.e., a
“wound that will not heal”; no fever or regional lym-
phadenopathy; typical nodular, indurated plaque or edema-
tous lesion; one or more painless chronic ulcers with
undermined edges or a depressed scar; swelling over a
painful joint, which suggested bone involvement; and
patient age <15 years; patient living or traveling in a dis-
ease-endemic zone.
Seventy patients were excluded from the study: 13 were
confirmed to have another disease (5 cases of cutaneous
tuberculosis, 4 M. chelonae abscesses, 2 cases of
mucormycosis, 1 case of cutaneous diphtheria, and 1
osteosarcoma), and 57 had recurrent BU (they constitute a
particular group of patients with long hospitalization times
or many recurrences), which left 1,630 patients for analy-
sis. We define a recurrent case as occurring in a patient
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Brussels, Belgiumwith a previous history of BU who has another lesion at the
same or different site of the body within 1 year of complet-
ing treatment (16). We define mixed forms as the simulta-
neous presence of different forms in the same patient at
one or multiple body sites.
Specimens of tissue and exudates from 906 patients
were analyzed by one or more of the following examina-
tions to confirm the clinical diagnosis: direct smear exam-
ination for acid-fast bacilli (AFB), culture, IS2404
polymerase chain reaction (PCR), and histopathologic
examination (17). The remaining 724 cases were diag-
nosed clinically; all were typical of BU and did not present
reasonable differential diagnostic problems.
Demographic data of the general population were taken
from the most recent national census (1992) (18).
Additional statistical information came from the “Benin
Demographic and Health Survey” (19). For the 5-year
period 1997–2001, demographic data were derived from
1992 statistics that assumed an annual 3.2% growth rate,
corrected by projections of 1996 of the National Institute
of Statistics and Economic Analysis of Benin.
Data were analyzed with EpiInfo (Centers for Disease
Control and Prevention, Atlanta, GA) and SPSS v. 9.0
(SPSS, Chicago, IL) for Windows. Contingency tables
were analyzed by the Pearson chi-square test, and non-
parametric tests of Mann-Whitney and Kruskal-Wallis
were applied to compare medians of asymmetric distribu-
tions. These medians are presented with the first quartile
(q1) and the third quartile (q3). Cases were excluded from
each analysis when information was missing for a specific
variable.
Results
Geographic Origin of Patients and 
Changes in Buruli Ulcer Admissions
CSNG ordinarily receives patients from the regions of
Zou, Oueme, Mono, and Atlantique (Figure 1). Most of the
patients whose data were analyzed came from the region of
Zou, where CSNG is located, followed by the regions of
Oueme, Atlantique, and Mono. Twelve patients were from
neighboring countries (Nigeria, Togo, Côte d’Ivoire, and
Ghana), and the origin of 24 was not recorded (Table 1).
BU has not been reported from the two northern regions of
Benin (Atacora and Borgou).
Figure 2 includes additional data going back to 1992 (4)
that show an increased number of patients in all regions of
southern Benin from 1992 to 1997, with a decrease in cer-
tain regions from 1998 to 2001. A gradual increase is seen
in the number of patients from the Oueme and Atlantique
regions admitted to CSNG from 1992 through 2001.
However, the number of patients from the Zou and Mono
regions increased from 1992 to 1998 and then decreased in
each region from 1999 to 2001.
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Table 1. Origin of Buruli ulcer cases, 1997–2001
a 
Region  1997  1998  1999  2000  2001  Total (%) 
Zou  224  229  221  196  195  1,065 (66.3) 
Oueme  35  45  90  46  64  280 (17.4) 
Atlantique  11  26  35  25  55  152 (9.5) 
Mono  17  42  26  6  6  97 (6.0) 
Other  3  2  2  3  2  12 (0.8) 
Total  290  344  374  276  322  1,606 
aOf cases in which region of origin was known. A total of 24 cases in the 5-year period were unknown.  
Figure 1. Map of Benin with the four Buruli ulcer–endemic regions:
the region of Zou (Z), the region of Atlantique (A), the region of
Mono (M), and the region of Oueme (O).Table 2 shows the number of BU patients for some dis-
tricts of Oueme, Atlantique and Zou regions. For the Zou
region, detection rates are also presented. In this region,
the number of BU patients coming from Abomey district
remained relatively constant from 1997 to 2001. The num-
ber of BU patients from Zogbodomey and Agbangnizoun
increased. During the same period, the number of patients
from Zagnanado and Ouinhi decreased. In the Oueme
region, patients from Bonou district increased, and patients
from the Adja-Ouere district decreased. In the Atlantique
region, the number of patients coming from the Ze district
increased notably from 1997 to 2001.
Data from 1992 are represented in Figure 3 for five dis-
tricts in the Zou region and in Figure 4 for two districts in
the Oueme region and one district in the Atlantique region.
In the five districts in Zou, the number of patients coming
to CSNG was higher in 1997 than in 2000, except for
Zogbodomey, where the number increased. From 1992 to
1997, the number of patients coming from Zagnanado and
Ouinhi districts increased. After 1997, these numbers
decreased to the 1992 level. For the three other districts,
the number of BU patients progressively increased from
1992 to 2001. Numbers of BU patients were highest in
1999 in the two districts of Oueme. The number of patients
coming from Ze in the Atlantique region doubled between
2000 and 2001. Data before 1992 are not reported because
they concern only 71 patients (4).
Clinical Form of Buruli Ulcer
Different forms of the disease are presented in Table 3.
Over the observation period, the percentage of ulcers
decreased from 41.0% to 18.3% while mixed forms
increased from 12.4% to 24.8%. The percentages of nod-
ules decreased from 1997 to 2001. A total of 7.6% of the
patients had osteomyelitis with no active cutaneous form.
The percentage of patients with osteomyelitis reached
13.2% when all patients were included. The clinical form
of the lesions was not reported for 19 patients. 
If bone and mixed forms are divided into ulcerated and
nonulcerated forms, the percentages of ulcerated and
nonulcerated forms remained relatively constant for the
entire study period. No statistical difference was found
between the percentage of ulcerated and nonulcerated
forms from 1997 to 2001 (data not shown).
Delay in seeking medical attention was related to clini-
cal form of the disease (Figure 5) (all patients during entire
study period). Median was 30 (q1 = 23, q3 = 58) to 46 days
(q1 = 15, q3 = 101) for nonulcerated forms (nodule,
edema, and plaque) and 61 days (q1 = 30, q3 = 122) for
ulcerated forms. Median delay for bone lesions was 91
days (q1 = 30, q3 = 213).
Comparison of the duration of hospitalization with the
clinical form is shown in Figure 6. Except for patients with
a nodule, who spent 20.5 days (q1 = 11, q3 = 32) at the hos-
pital, median times of hospitalization for all patients with
each form of disease during the study period was from 23.0
(q1 = 21, q3 = 52) to 49.5 days (q1 = 18.5, q3 = 90).
Median patient delay in seeking medical care (for all
clinical forms) over the study period was 46 days (Table
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Figure 2. Number of Buruli ulcer (BU) patients by region,
1992–2001.
Table 2. Changes in number of Buruli ulcer patients in some districts of the Zou, Oueme, and Atlantique regions, 1997–2001
a 
Region  District  1997, N (DR)  1998, N (DR)  1999, N (DR)  2000, N (DR)  2001, N (DR) 
Abomey  11 (13.9)  12 (14.7)  16 (19.0)  10 (11.5)  13 (14.6) 
Agbangnizoun  15 (26.2)  11 (18.6)  22 (36.2)  16 (25.5)  22 (34.1) 
Ouinhi  73 (204.3)  65 (176.6)  53 (139.8)  38 (97.3)  32 (79.6) 
Zagananado  76 (185.9)  68 (161.5)  37 (85.3)  41 (91.8)  52 (113.0) 
Zou 
Zogbodomey  18 (25.8)  23 (32.0)  32 (43.2)  32 (42.0)  25 (31.8) 
Adja-Ouere  7  14  15  6  4  Oueme 
Bonou  23  23  58  29  32 
Atlantique  Ze  3  14  22  21  47 
aDR, detection rate per 100,000 population.  4). In 1997, median delay was 57 days, while in 2001 delay
was reduced to 30 days. Overall median delay at CSNG
from 1989 to 2001 declined from approximately 4 months
to 1 month (Figure 7). Median hospital stay at CSNG from
1989 to 2001 declined from approximately 9 months to 1
month (Figure 8).
In 2000, the method of referral of BU cases to CSNG
was recorded. Patients previously treated at CSNG recom-
mended treatment at CSNG for 68.3% of the patients;
22.1% were referred by a family member acquainted with
CSNG, and 5.9% were referred by village outreach activi-
ties of CSNG. Only 3.7% of the patients were referred by
a government health center or a health professional.
Discussion
In 1997, Aguiar et al. (4) reported characteristics of 867
BU patients in southern Benin for 1992 to 1996. Our study
supplements their data with an analysis of BU patients
seen at the same medical center over the succeeding 5
years.
As was shown in 1992 to 1996, data collected from
1997 to 2001 indicate that CSNG receives patients mainly
from the Zou region, where the center is located. Patients
choose CSNG for a variety of reasons, including accessi-
bility, financial concerns, and cultural compatibility.
However, two new developments somewhat altered the
data for the two periods. The first development was that in
1998, a new treatment center for BU was established at
Lalo in the Mono region. This development moderately
decreased the number of patients coming to CSNG from
this region. Approximately 400 BU patients were treated at
Lalo from 1998 through 2001. The second development
was that from 1999 through 2001, more patients from the
Atlantique and Oueme regions came to CSNG because of
active public health programs that raised awareness of BU
and the availability of treatment at the facility. During this
period, these regions had no treatment centers.
Active case finding performed in the Zou region in
2000 did not result in an increase in the number of BU
patients coming from this region. CSNG is well known
and highly respected by the population, but some patients
refuse to go to it, usually for cultural reasons. Aujoulat et
al. (20) published a report on the psychosocial aspects of
health-seeking behaviors of patients with BU in southern
Benin. Their study indicates that some patients are reluc-
tant to seek treatment at any health center. In addition, our
own experiences confirm that some BU patients actively
avoid detection and would never be included in official
reports. These patients, therefore, would not be identified
by active or passive detection methods. We conclude that
rates for the Zou region are a valid estimate of the inci-
dence of the disease, even if the rates are slightly underes-
timated. A comparison of detection rates of BU in the Zou
region with those of leprosy and tuberculosis in 1999
shows a higher rate of BU (21.5/100,000) than of leprosy
(13.4/100,000) and tuberculosis (20.0/100,000) (19).
regional differences in the prevalence of BU exist, and the
disease is believed to be severely underreported. 
A few BU-endemic countries have reported national
data on prevalence and incidence. For Uganda in 1972,
Barker (8) reported incidence >500/100,000 in some
regions. In Ghana, Amofah et al. (5) estimated a preva-
lence of 22% in some villages of the Amansie District and
a national prevalence of 20.7/100,000 (21). Marston et al.
(7) found a local prevalence of 16.3% in the Daloa region
of Côte d’Ivoire. Seasonal variations in the frequency of
BU have been reported in several countries (9,10).
Environmental alterations may cause changes in BU
frequency (9). Moreover, search for environmental M.
ulcerans DNA detected variations in positivity rates of
specimens over time, and these changes are reflected in
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Figure 3. Number of Buruli ulcer patients from five districts of the
Zou region who were admitted to the Centre Sanitaire et
Nutritionnel Gbemoten (Benin), 1992–2001.
Figure 4. Buruli ulcer (BU) in two districts of the Oueme region and
one district of Atlantique region, 1992–2001.corresponding alterations of frequency of BU patients in
the same foci (Portaels et al., unpub. data). The focal
nature of BU prevalence is important in determining the
overall disease rate.
Discrepancies between some published reports and our
data are partly explained by factors that influenced fre-
quencies in different BU-endemic regions in Benin. In the
Zou region between 1992 and 1997, treatment facilities at
CSNG developed markedly. This effort became even more
efficient after 1997, as a result of aid from the Directorate-
General for Development Cooperation (DGDC, Belgium),
beginning in 1998. In the Mono region, the Médecins Sans
Frontières–Luxembourg established a BU treatment facili-
ty in 1998 and conducted rural public health training and
publicity programs. In the Oueme and Atlantique regions,
Raoul Follereau France and Luxembourg Foundations
conducted population surveys in 1999 for the future devel-
opment of treatment centers in these regions.
The drop in frequencies after these peak years, perhaps
related to reduced rural public health education activities,
fell to pre-1997 levels, when detection was totally passive.
This effect could be explained by cyclic environmental
changes, such as excessively dry or wet periods that differ
from region to region. Data for Ouinhi and Zagnanado in
the Zou region have been collected since 1992 (Figure 3).
From 1992 through 1996, frequencies in these two districts
increased rapidly, probably because more BU patients had
become aware of the effective therapy offered by CSNG.
Detection of BU reached its highest level in 1997. 
Reductions in new cases from Ouinhi and Zagnanado,
beginning in 1998, may be attributable to any number of
factors. After the intensive publicity on BU was discontin-
ued, inhabitants may have begun to lose interest. After the
intensive campaign, traditional practitioners’interest in the
disease may have increased, and they may have promoted
their treatment methods in their respective villages.
Because of fear of surgery and lack of local access to prac-
titioners, patients may initially prefer traditional therapists,
who do not perform surgery. Transportation costs are min-
imized by frequenting local practitioners (22). The active
program may have reduced the reservoir of untreated
patients. Possibly, disease-endemic sites may have become
less contaminated with M. ulcerans. Environmental stud-
ies show that some disease-endemic sites in the district of
Ouinhi became less frequently positive for M. ulcerans
DNA (Portaels et al., unpub. data).
As shown in Figure 3, BU frequencies remain nearly
constant for three districts (Abomey, Agbangnizoun, and
Zogbodomey). Frequency in the Ze district (Figure 4)
increased in 2001, which may be attributed to active pub-
lic health publicity campaigns. Abomey and
Agbangnizoun districts are in the Kouffo River basin
(Figure 1) rather than the Zou and Oueme basins, and
Zogbodomey is more closely related to the Kouffo than to
the Zou basin. This finding suggests that changes in the
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Table 3. Clinical signs and symptoms of Buruli ulcer by year  
Clinical form   1997, n (%)  1998, n (%)  1999, n (%)  2000, n (%)  2001, n (%)  Total, n (%) 
Nodule  35 (12.1)  35 (10.1)  13 (3.5)  20 (7.2)  19 (5.9)  122 (7.6) 
Edema  1 (0.3)  6 (1.7)  1 (0.3)  3 (1.1)  1 (0.3)  12 (0.7) 
Plaque  66 (22.8)  98 (28.2)  123 (32.9)  72 (25.9)  111 (34.4)  470 (29.1) 
Ulcer  119 (41.0)  99 (28.4)  109 (29.1)  72 (25.9)  59 (18.3)  458 (28.4) 
Bone  29 (10.0)  23 (6.6)  31 (8.3)  16 (5.8)  23 (7.1)  122 (7.6) 
Mixed  36 (12.4)  69 (19.8)  78 (20.9)  79 (28.4)  80 (24.8)  342 (21.2) 
Healed ulcer  4 (1.4)  14 (4.0)  14 (3.7)  15 (5.4)  29 (9.0)  76 (4.7) 
Other  0  4 (1.1)  4 (1.1)  1 (0.4)  0  9 (0.6) 
Total bone
a  40 (13.8)  49 (14.1)  55 (14.7)  35 (12.6)  34 (10.5)  213 (13.2) 
Total  290  348  373  278  322  1611 
aCombined osteomyelitis with no associated active cutaneous form and mixed forms with bone lesions.  
Figure 5. Median patient delay and interquartile range by Buruli
ulcer (BU) clinical form.BU rates in the Abomey, Agbangnizoun, and Zogbodomey
districts remained stable because of common hydrologic
relationships. Differences in number of cases coming from
the districts of Ouinhi/Zagnanado and Agbangnizoun/
Abomey/Zogbodomey could be related to uninvestigated
environmental differences in the two different basins.
Other scientists (23,24) reported osteomyelitis in BU
patients; in this study, bone involvement was frequent
(13.2%). As shown in Figure 5, the form of disease is relat-
ed to the period of delay in seeking medical attention.
Nonulcerated forms have a median delay of 1 to 1.5
months, ulcers 2 months, and patients with osteomyelitis 3
months. This finding has several possible explanations.
The nonulcerated form is the first stage of the disease in
the nodular, edematous, or plaque form. After a variable
period of time (a few weeks to several months), these
forms ulcerate. Also, disseminated bone lesions take
approximately 3 months to develop. Because open skin
lesions may not be visible at the site of the bone lesion, the
disease may go undetected or disregarded for long periods.
Lesions may also arise by reactivation of subclinical latent
foci (15).
In 1997, Aguiar et al. (4) described 867 BU cases, of
which 94% were ulcerated. Improved knowledge on clini-
cal classification of BU has led to recognizing a higher
percentage of nonulcerated and mixed forms and fewer
patients with ulcers. Nodules are less common in Benin.
The present study shows that the percentage of ulcerated
and nonulcerated forms of the disease was approximately
50% from 1997 to 2001 and that the fluctuation in the per-
centage of ulcerated and nonulcerated stages was insignif-
icant. We attribute the difference in the percentage of
ulcerated forms before 1997 to delayed admission to the
hospital in 1989 to 1996. However, in spite of the reduced
delay in admission after 1997, we have not observed an
increased number of nodules. The reason for the reduced
rate of nodular disease in Benin remains obscure.
Median patient delay in admission to hospital
decreased from 1997 through 2001. From 1998 through
1999, the difference was not significant, but it became sig-
nificant between 1999 and 2000 (Table 4). Introduction of
the DGDC’s “Ulcère de Buruli au Bénin” Program in 1998
was an important factor in the marked reductions in patient
delay. Moreover, in 2000, promotional sessions on BU
were organized by DGDC and the National BU Program
PNLUB (Programme National de Lutte contre l’UB) in the
Zou, Oueme, and Atlantique regions. After these efforts,
patients reported earlier to the center than in 1999.
Median duration of hospitalization decreased from
1997 through 2001. These changes could be attributed to
reduced patient delay (earlier care-seeking by patients with
less severe lesions, especially those with ulcers and bone
involvement) or improved patient care at the health center.
Except for patients with nodules, patients with all other
forms of the disease are usually hospitalized for 1 to 2
months (Figure 6). Under field conditions in BU-endemic
countries, we believe this period of hospitalization is
unlikely to be further reduced significantly for advanced
BU disease with the current therapies.
Referral of patients to CSNG for treatment depended
largely on word-of-mouth suggestions by former BU
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Figure 6. Median duration of hospitalization and interquartile range
by Buruli ulcer (BU) clinical form.
Table 4. Changes in patient delay and duration of hospitalization in Buruli ulcer patients, 1997–2001 
Year  Median patient delay (q1–q3)  p  Median duration of hospitalization (q1–q3)  p 
1997  57 (30–91)  NS
a  39 (31–53)  NS
a 
1998  61 (30–91)  NS
a  39 (28–54)  < 0.001
a 
1999  46 (23–122)  0.001
a  35 (26–43)  0.009
a 
2000  30 (23–61)  NS
a  33 (23–42)  NS
a 
2001  30 (23–61)    32 (24–44)   
Total  46 (23–91)  < 0.001
b  35 (26–48)  < 0.001
b 
aMann-Whitney nonparametric test. Significance level = 0.0125 (Bonferroni correction for pair comparison = 0.05/4). NS = nonsignificant.  
bKruskal-Wallis nonparametric test. Significance level = 0.05.  patients. Patients now tend to bypass traditional therapists
and go to CSNG. Accepting surgical treatment remains a
deterrent to seeking institutional therapy (20). In these
cases, former patients often provide the incentive to seek
appropriate therapy. In 2000, a high percentage (68.3%) of
patients was referred to CSNG by a previously treated
patient.
While some health workers suggest that clinical fea-
tures are sufficient to diagnose BU, in our experience, bac-
teriologic and histopathologic evaluations remain
important for disease confirmation. This fact is especially
true for all research projects on BU. Numerous conditions
may present differential diagnostic problems, including
parasitic infections, mycotic diseases, neoplastic condi-
tions, tropical phagedenic and stasis ulcers, and cutaneous
tuberculosis. In our study a disease other than BU was con-
firmed in 13 (1.4%) of 906 patients by bacteriologic or
histopathologic analysis.
In conclusion, data from a rural hospital at Zagnanado
show that BU is highly endemic in southern Benin. Our
study highlights the importance of a team approach for
optimal management of M. ulcerans disease, both at the
village and treatment center levels. Such strategies should
include efforts in early diagnosis and effective therapy that
are compatible with the socioeconomic structure (25).
These goals were largely achieved in Benin because of the
implementation of an International Cooperation Program
and the creation of a national BU Program.
We believe that a multidisciplinary approach that
involves educating the population, training healthcare
workers, adequately managing cases, and simplifying sur-
gical procedures reduced hospitalization time and stimu-
lated patient initiative. All these approaches improve
patient outcome and lower the socioeconomic effect of the
disease on rural populations.
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